Intellia is a leading genome editing company, focused on the development of potentially curative therapeutics utilizing the CRISPR/Cas9 system. The Company’s mission is to develop gene editing treatments that can positively transform the lives of people living with severe and life-threatening diseases.
There are currently no events scheduled.
CFO & Head of Investor Relations
+1 857 706 1081